Drug
Delpazolid clinical trials
Also written LCB01-0371.
- studies test it
- 13
- open now
- 2
- in phase 3
- 0
- first study started
- 2012
Keep track of what changes. Save the delpazolid studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
13 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 2 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 2
LigaChem Biosciences, Inc. (11) · University College, London (1) · Michael Hoelscher (1)
Often tested with
Tested in the same studies.
Linezolid (2) · Ganfeborole (2) · BTZ-043 (2) · Pretomanid (2) · Moxifloxacin (2) · Pyrazinamide (2) · Bedaquiline (1) · OPC-67683 (1)
Studies
Open first, then newest update. How each study uses delpazolid is read from its arms, and is right about nine times in ten.
Testing it · 13
- Platform Assessing Regimens and Durations In a Global Multisite Consortium for TBRecruitingPhase 2University College, LondonNCT06114628Written as Delpazolid (DZD)
- PanACEA - STEP2C -01RecruitingPhase 2Michael HoelscherNCT05807399Written as Delpazolid (LCB01-0371)
- Study to Evaluate the Efficacy of Delpazolid as Add-on Therapy in Refractory Mycobacterium Abscessus ComplexCompletedPhase 2LigaChem Biosciences, Inc.NCT06004037Written as Delpazolid
- PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)CompletedPhase 2LigaChem Biosciences, Inc.NCT04550832Written as Delpazolid
- A Phase 2a Study, Effect of Vancomycin With vs Without Delpazolid (LCB01-0371) in Patients With MRSA BacteremiaTerminatedPhase 2LigaChem Biosciences, Inc.NCT05225558Written as Delpazolid
- Trial to Evaluate Bioequivalence of LCB01-0371 in Different BatchesCompletedPhase 1LigaChem Biosciences, Inc.NCT04939779Written as LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R)
- A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PKCompletedPhase 2LigaChem Biosciences, Inc.NCT02836483Written as LCB01-0371 800mg, QD
- IV Dosage Form of LCB01-0371 Phase I Study in Healthy Male VolunteersCompletedPhase 1LigaChem Biosciences, Inc.NCT02882789Written as LCB01-0371
- An Open-label, Single Dose, Parallel Design, Phase 1 Clinical Study of LCB01-0371TerminatedPhase 1LigaChem Biosciences, Inc.NCT02529241Written as Group 1:LCB01-0371
- To Evaluate the Effect of Food on Pharmacokinetics(PK), Phase I Clinical Study of LCB01-0371CompletedPhase 1LigaChem Biosciences, Inc.NCT02538003Written as LCB01-0371 Tablet 800 mg(R)
- Multiple Ascending Dose, Phase 1 Clinical Study of LCB01-0371CompletedPhase 1LigaChem Biosciences, Inc.NCT02540460Written as LCB01-0371 800mg
- Multiple Ascending Dose Study for LCB01-0371CompletedPhase 1LigaChem Biosciences, Inc.NCT01842516Written as LCB01-0371 800mg
- A Clinical Study, Randomized, Double-blind, Placebo-controlled, Single Dose StudyCompletedPhase 1LigaChem Biosciences, Inc.NCT01554995Written as LCB01-0371
Codes
What other systems call delpazolid · ClinicalTrials.gg INT000930
- MeSH (NLM) C000627008delpazolidConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 43EP6XV33EDELPAZOLIDConfirmed FDA, NLM, Wikidata
- Wikidata Q27258646delpazolidConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166717DelpazolidOne source FDA
- DrugBank DB13077One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000627008 | delpazolid | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 43EP6XV33E | DELPAZOLID | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27258646 | delpazolid | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166717 | Delpazolid | One source FDA |
| DrugBank | DB13077 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.